Description of Medical ServiceThe primary clinical purpose for monitoring minimal residual disease (MRD) is to determine the response to treatment and the risk of leukaemia relapse. Next Generation Sequencing (NGS) is a method which can be used to quantify and evaluate MRD. It involves the collection of genomic DNA from bone marrow aspirate or peripheral blood, which is then processed to identify the frequency and distribution of clonal sequences consistent with a malignant lymphoma and to quantify MRD over time in these patients.
Description of Medical ConditionAcute lymphoblastic leukaemia (ALL) can occur at any age, but most cases arise in children younger than six years of age. Typical symptoms include fever, fatigue, bone or joint pain, bleeding, anorexia, abdominal pain, and hepatosplenomegaly. Despite most patients achieving a morphological remission, many will still have persistent MRD, which is the strongest predictor of relapse in ALL.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 2817 KB)
Application Form (Word 1229 KB)
Consultation SurveyConsultation Survey (PDF 691 KB)
Consultation Survey (Word 72 KB)
PASC consultation closed
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO ConfirmationPICO Confirmation (PDF 794 KB)
PICO Confirmation (Word 333 KB)